[go: up one dir, main page]

WO2009100243A3 - Elavl4 as a predictor of depression in alzheimer's disease and parkinson's disease patients - Google Patents

Elavl4 as a predictor of depression in alzheimer's disease and parkinson's disease patients Download PDF

Info

Publication number
WO2009100243A3
WO2009100243A3 PCT/US2009/033253 US2009033253W WO2009100243A3 WO 2009100243 A3 WO2009100243 A3 WO 2009100243A3 US 2009033253 W US2009033253 W US 2009033253W WO 2009100243 A3 WO2009100243 A3 WO 2009100243A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
elavl4
parkinson
alzheimer
depression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/033253
Other languages
French (fr)
Other versions
WO2009100243A2 (en
Inventor
Michael A. Slifer
Gary W. Beecham
Eden R. Martin
Gaofeng Wang
John R. Gilbert
Jonathan L. Haines
Jeffrey Vance
Margaret A. Pericak-Vance
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Miami
Vanderbilt University
Original Assignee
University of Miami
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Miami, Vanderbilt University filed Critical University of Miami
Publication of WO2009100243A2 publication Critical patent/WO2009100243A2/en
Publication of WO2009100243A3 publication Critical patent/WO2009100243A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Methods of screening patients with Alzheimer's Disease or Parkinson's Disease for risk of late-onset depression, by assaying a biological sample for the presence of ELAVL4.
PCT/US2009/033253 2008-02-05 2009-02-05 Elavl4 as a predictor of depression in alzheimer's disease and parkinson's disease patients Ceased WO2009100243A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US690308P 2008-02-05 2008-02-05
US61/006,903 2008-02-05

Publications (2)

Publication Number Publication Date
WO2009100243A2 WO2009100243A2 (en) 2009-08-13
WO2009100243A3 true WO2009100243A3 (en) 2009-11-05

Family

ID=40952685

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/033253 Ceased WO2009100243A2 (en) 2008-02-05 2009-02-05 Elavl4 as a predictor of depression in alzheimer's disease and parkinson's disease patients

Country Status (1)

Country Link
WO (1) WO2009100243A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060068428A1 (en) * 2003-11-03 2006-03-30 Duke University Identification of genetic markers associated with parkinson disease
WO2006105907A1 (en) * 2005-04-06 2006-10-12 Diamed-Eurogen N.V. Neurodegenerative markers for psychiatric conditions
US20060257903A1 (en) * 2005-03-31 2006-11-16 Huda Akil Compositions and methods for diagnosing and treating neuropsychiatric disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060068428A1 (en) * 2003-11-03 2006-03-30 Duke University Identification of genetic markers associated with parkinson disease
US20060257903A1 (en) * 2005-03-31 2006-11-16 Huda Akil Compositions and methods for diagnosing and treating neuropsychiatric disorders
WO2006105907A1 (en) * 2005-04-06 2006-10-12 Diamed-Eurogen N.V. Neurodegenerative markers for psychiatric conditions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HAUGARVOLL, K. ET AL.: "ELAVL4, PARK10, and the Celts", MOV. DISORD., vol. 22, no. 4, 15 March 2007 (2007-03-15), pages 585 - 587 *
NOUREDDINE, M. A. ET AL.: "Association between the neuron-specific RNA-binding protein ELAVL4 and Parkinson disease", HUM. GENET., vol. 117, no. 1, June 2005 (2005-06-01), pages 27 - 33 *

Also Published As

Publication number Publication date
WO2009100243A2 (en) 2009-08-13

Similar Documents

Publication Publication Date Title
WO2010045490A3 (en) Human biomarker hypermapping for depressive disorders
WO2007087139A3 (en) MESENCHYMAL STEM CELLS EXPRESSING TNF-α RECEPTOR
GB2434205B (en) Module for preparing a biological sample, biochip-assembly and use of the module
WO2010132479A3 (en) Methods for the diagnosis of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
WO2005114190A3 (en) Methods of identifying biomarkers
WO2009121032A3 (en) Sample preparation devices and methods for processing analytes
WO2007076439A3 (en) Methods and marker combinations for screening for predisposition to lung cancer
WO2007039319A8 (en) Dna microarray for rapid identification of candida albicans in blood cultures
WO2010005982A3 (en) Multiplexed biomarkers of insulin resistance
IL185501A0 (en) Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof
EP3284469A3 (en) Compositions and methods for detection of lysosomal storage disease
WO2006023719A3 (en) Identification of snp’s associated with schizophrenia, schizoaffective disorder and bipolar disorder
WO2005099716A3 (en) Method for analyzing the biological age of a subject
EP2700723A3 (en) Novel single nucleotide polymorphisms and combinations of novel and known polymorphisms for determining the allele-specific expression of the IGF2 gene
WO2010028373A3 (en) Methods for diagnosing cancer and determining the overall survival and disease-free survival of cancer patients
WO2011143574A3 (en) Plasma biomarkers for diagnosis of alzheimer's disease
IL223077A0 (en) Novel as160-like protein, test systems, methods and uses involving it for the identification of diabetes type 2 therapeutics
AU2010202926B2 (en) Markers and methods relating to the assessment of Alzheimer's disease
WO2008112898A3 (en) Genetic alterations on chromosome 12 and methods of use thereof for the diagnosis and treatment of type 1 diabetes
WO2011143575A3 (en) smFRET WITH MEMBRANE PROTEINS
WO2009129472A3 (en) Methods of labeling biological samples
WO2008065682A3 (en) Genetic susceptibility variants of type 2 diabetes mellitus
WO2007038264A3 (en) Gapr-1 methods
WO2008090177A3 (en) Diagnosis of prostate cancer
EP1891240A4 (en) Method for producing improved gene expression analysis and gene expression analysis comparison assay results

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09708407

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09708407

Country of ref document: EP

Kind code of ref document: A2